Retinal Reports

Market Scope uses a multi-source methodology when preparing our annual and quarterly reports. We incorporate surgeon surveys, our extensive database of physicians and surgery centers, disease models, clinical studies, financial reports, and more. Our wide-ranging knowledge of products and technology and our comprehensive network of industry contacts also contribute to our coverage on the ophthalmic industry.

2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases, October, 2024

The “2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases” analyzes the market for complement inhibitors, gene therapies, antioxidants, sustained-release devices, and other treatments for geographic atrophy, dry AMD, and additional nonexudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines disease prevalence, reviews patient economics and reimbursement, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 19 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases, September, 2024

The “2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases” analyzes the market for anti-VEGFs and other drugs for the treatment of exudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines the market’s evolution, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 40 competitors are profiled, with discussion of their products, strategic market position, background, and outlook. 

Want to Purchase the Full Report?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more